JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Search

Denali Therapeutics Inc

Fechado

SetorSaúde

20.24 0.65

Visão Geral

Variação de preço das ações

24h

Atual

Mín

19.96

Máximo

20.53

Indicadores-chave

By Trading Economics

Rendimento

-1.6M

-129M

Funcionários

503

EBITDA

8.9M

-125M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+80.18% upside

Dividendos

By Dow Jones

Próximos Ganhos

4 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

5.6K

3.3B

Abertura anterior

19.59

Fecho anterior

20.24

Sentimento de Notícias

By Acuity

46%

54%

171 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Denali Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de abr. de 2026, 00:00 UTC

Notícias Principais

Australian Flash PMI Bounce in April Conceals Deeper Worries

22 de abr. de 2026, 23:33 UTC

Ganhos

SK Hynix Posts Record Quarterly Results Amid AI Boom

22 de abr. de 2026, 22:40 UTC

Ganhos

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22 de abr. de 2026, 22:10 UTC

Aquisições, Fusões, Aquisições de Empresas

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22 de abr. de 2026, 21:11 UTC

Ganhos

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22 de abr. de 2026, 21:01 UTC

Ganhos

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22 de abr. de 2026, 23:46 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

22 de abr. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22 de abr. de 2026, 23:34 UTC

Conversa de Mercado
Notícias Principais

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22 de abr. de 2026, 23:16 UTC

Ganhos

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22 de abr. de 2026, 23:15 UTC

Ganhos

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22 de abr. de 2026, 22:54 UTC

Ganhos

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22 de abr. de 2026, 22:54 UTC

Ganhos

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22 de abr. de 2026, 22:52 UTC

Ganhos

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22 de abr. de 2026, 22:51 UTC

Ganhos

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22 de abr. de 2026, 22:31 UTC

Ganhos

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22 de abr. de 2026, 22:31 UTC

Ganhos

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22 de abr. de 2026, 22:30 UTC

Ganhos

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22 de abr. de 2026, 22:30 UTC

Ganhos

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22 de abr. de 2026, 22:29 UTC

Ganhos

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22 de abr. de 2026, 22:28 UTC

Ganhos

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22 de abr. de 2026, 22:28 UTC

Ganhos

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22 de abr. de 2026, 22:27 UTC

Ganhos

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22 de abr. de 2026, 22:06 UTC

Conversa de Mercado
Ganhos

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22 de abr. de 2026, 21:55 UTC

Aquisições, Fusões, Aquisições de Empresas

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22 de abr. de 2026, 21:47 UTC

Ganhos

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 de abr. de 2026, 21:37 UTC

Ganhos

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22 de abr. de 2026, 21:34 UTC

Ganhos

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22 de abr. de 2026, 21:29 UTC

Ganhos

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 de abr. de 2026, 21:20 UTC

Conversa de Mercado
Ganhos

Tesla Expands Manufacturing to Chips -- Market Talk

Comparação entre Pares

Variação de preço

Denali Therapeutics Inc Previsão

Preço-alvo

By TipRanks

80.18% parte superior

Previsão para 12 meses

Média 36.27 USD  80.18%

Máximo 42 USD

Mínimo 30 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

14 ratings

13

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

13.355 / 16.44Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Neutral Evidence

Longo Prazo

Strong Bearish Evidence

Sentimento

By Acuity

171 / 348 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat